Organic Active Ingredients TRIZ Cases

Segmented hydroxyester structures inhibit Bcl-2 family proteins, overcoming chemoresistance by restoring apoptotic activity in tumor cells.

Benzomorpholine derivatives resolve efficacy and exposure trade-offs by lowering ED50 values to reduce tumor volume.

Segmented pyrrolobenzodiazepine dimers released from CD25-targeting antibodies kill neighboring CD25-negative tumor cells through a bystander effect.

Substituted cyclobutyl benzimidazole compounds selectively inhibit the phosphodiesterase 10 enzyme to modulate neuronal signaling pathways.

Segmented chemical structures modulate c-kit kinase activity to resolve the trade-off between therapeutic effectiveness and treatment versatility.

Fused aminodihydrothiazine derivatives inhibit beta-secretase 1 activity to reduce amyloid-beta production.

Using viral vectors to deliver Pdx-1 and growth factors for in vivo beta cell formation, addressing insulin scarcity and immune rejection.

Processed calcium aluminosilicate clay sequesters aflatoxins via selective adsorption, reducing toxicity without interfering with essential nutrient absorption.

Degradable cationic lipids enhance delivery efficacy while reducing systemic toxicity through hydrolyzable linkers.

Ethynyl derivatives reduce CNS side effects by limiting efficacy below sixty percent while maintaining therapeutic effects on mGluR5 receptors.

Nitrogen flushing and oxygen-absorbing packaging prevent oxidative degradation, enabling stable epinephrine storage without refrigeration.

N-acetyl-DL-leucine counters age-related visual sensitivity decline by boosting retinal energy metabolism and antioxidant defenses.

Indazole compounds inhibit proinflammatory cytokines, reducing biomarkers and treating inflammatory diseases.

Benzothiazole salt polymorphs improve solubility via acid counterions to overcome poor physicochemical properties for effective c-abl inhibition.

Palladium and copper catalysts with phosphine ligands synthesize 4H-pyrazolo[1,5-α]benzimidazoles via mild conditions, reducing reagent toxicity.

Segmented measurement of L-tryptophan, serotonin, and melatonin receptor 1A identifies specific biochemical deficiencies to guide therapeutic intervention.

A hydrogel composition combines reactive and initiated precursors to form an interpenetrating network.

Formula I compounds inhibit KDM5 demethylases, preventing rapid drug resistance in cancer therapies.

Low molecular weight amino sugars plasticize polyvinyl alcohol matrices to lower processing temperatures during melt extrusion.

Biologically compatible compositions protect immobilized entities from conformational changes during mechanical manipulation.

Formula I compounds inhibit FLT3 and IRAK4 kinases, preventing resistant mutations in acute myeloid leukemia.

Celastrol treats cholestatic liver disease by regulating the SIRT1-FXR pathway, reducing bile acid synthesis and alleviating liver injury.

Administers celecoxib alongside BCG to block PGE2 synthesis, resolving prostaglandin-mediated suppression of CD8+ T cell responses.

Agent targets injured mesothelial cells to prevent surgical adhesions, resolving the trade-off between treatment complexity and effectiveness.

A composition containing compound K stimulates endogenous androgen production through ginseng-derived active ingredients.

Atomic layer deposition coats pharmaceutical substrates to resolve low yield and stability issues in solid dosage manufacturing.

Administering MOR00208 seven days before low-dose venetoclax reduces tumor burden, preventing acute tumor lysis syndrome while maintaining therapeutic efficacy.

Polymer blends with controlled polydispersity maintain structural integrity to prevent depot migration and reduce patient trauma during chronic pain treatment.

Ipolamiide extracts isolate specific compounds to inhibit CD8+ T cells, addressing poor selectivity in conventional immunosuppressants.

Synthetic analogs replace unstable natural ligands to treat peripheral and inflammatory pain conditions.

Amphiphilic infiltration agents accelerate denaturant penetration into biological tissue, preventing dehydration artifacts common in alcohol-based fixatives.

L-DNA nanocages resist nuclease degradation through chirality inversion, preventing sequence interference during self-assembly.

Glucosyltransferase-catalyzed carbohydrate transfer creates cannabinoid glycosides that improve solubility while avoiding unnatural synthetic compositions.

Stabilized oltipraz rotomeric complexes enhance transcription factor Nrf2 up-regulation, addressing formulation optimization complexity.

Inhaled formula I urea derivatives inhibit p38 MAPK to reduce inflammatory cytokines, addressing insufficient potency of current therapies.

A biotechnological process using recombinant bacteria expressing human CYP450 enzymes to produce liver-specific metabolites.

D-serine targets GluN3-containing NMDARs on microglia and astrocytes, converting harmful neurotoxic responses into neuroprotective effects.

A cobimetinib preparation method uses acyl cyanation and a chiral auxiliary to establish enantiomeric purity in early synthesis steps.

Methionine, lysine, and histidine prevent protein denaturation without lyophilization.

Thiazole-substituted aminoheteroaryl compounds resolve limited efficacy of prior Syk inhibitors by enhancing binding affinity to treat inflammatory diseases.

Modified oligonucleotides target LRRK2 mRNA to reduce expression, addressing limited therapeutic options for Parkinson's Disease.

Novel thiazole derivatives with specific structural features treat ulcerative colitis, reducing side effects while maintaining therapeutic efficacy.

Nanoparticles encapsulate glutaminase inhibitors to overcome poor solubility and resistance, achieving sustained tumor drug exposure.

A non-aqueous patch uses a biaxially-oriented stretch cloth support to maintain strong adhesion on skin.

Replacing polar excipients with oleic acid surfactant in R-152a propellant prevents nozzle blockage while minimizing throat irritation.

Imidazopyridine compounds activate soluble guanylate cyclase independently of heme groups, bypassing resistance and side effects from NO donors.

A spray drying process atomizes an aqueous ibuprofen and L-arginine solution into a fluidized sucrose bed to form solid granules.

FBXO7 and EYA2 inhibitors block AXL signaling to restore anti-PD-1 therapy response in Fbxw7 mutant tumors.

A cinacalcet oral solution uses propylene glycol and polyethylene glycol to dissolve the salt.

Empagliflozin treats type 2 diabetes in renal impairment by reducing hypoglycemia risk and weight gain via parameter changes.

A naphthoquinone compound suppresses allergic symptoms by inhibiting the degranulation of mast cells and basophils.

PEG oligomer conjugation shields fentanyl from first-pass metabolism and central nervous system penetration to enhance mu receptor specificity.

Profiles AML patients using molecular markers to predict kinase inhibitor efficacy, reducing relapse rates from non-specific chemotherapy.

Glutamic acid derivatives activate the calcium sensing receptor to provide therapeutic benefits for diarrhea while imparting the kokumi taste sensation.

Alkaline conversion of dihydromyricetin and resin elution resolve low purity interference in myricetin extraction.

Recombinant monoclonal antibodies target the RSV fusion protein to reduce dosage requirements and donor dependency.

Cas12i nucleases mediate precise TTR gene cleavage via specific PAM recognition, reducing off-target effects compared to SpCas9 systems.

Compound A treats biliary tract cancer by reducing tumor volume and maintaining stable disease periods in patients resistant to other chemotherapies.

Sulfobutylether beta-cyclodextrin inclusion complexes increase meloxicam solubility, resolving poor aqueous dissolution to deliver rapid migraine pain relief.

A novel Eluxadoline and methyl nicotinate co-crystal structure provides stable molecular packing.

Glycols protect vitamin B12 from degradation during storage, maintaining potency in injectable formulations.

Inhaled 3-amino pyrrolidine derivatives inhibit JAK kinases locally, minimizing systemic side effects while treating asthma and COPD.

Novel steroidal compounds inhibit steroid sulphatase and dehydrogenase enzymes to block estrogen synthesis pathways.

A nitric oxide-sensitive acrylamide-based polymer scavenges excess gas to alleviate inflammation.

Inhibiting METTL3 restricts SARS-CoV-2 replication while preserving host cell viability.

Propellant-free aqueous spray delivers betamethasone via oleyl alcohol, resolving the trade-off between improved drug absorption and reduced skin irritation.

Cyclodextrin encapsulation eliminates food effects on vilazodone bioavailability, allowing consistent pharmacokinetics regardless of meal intake.

Merges phytosphingosine with adenosine to boost VEGF expression in dermal papilla cells, resolving inconsistent individual efficacy.

Segmented micro-dystrophin constructs address fibrosis risks by delivering specialized domains to cardiac and skeletal muscles via catheter-based methods.

Specific oligosaccharide concentrations improve glucose management and reduce metabolic disorder risks in vulnerable infants.

Depletes immunosuppressive B cells using anti-CD19 antibodies to overcome treatment resistance and enable tumor eradication.

Selective water-soluble coating on bisphosphonate particles reduces gastric irritation while maintaining bioavailability.

A humanized anti-c-Met antibody conjugated with cytotoxic drugs delivers toxins directly to cancer cells expressing the c-Met receptor.

Triggered entities emit electromagnetic radiation to modulate target biological states without direct contact.

Sodium gluconate chelates metal ions to reduce bitterness by up to 80% without compromising flavor profiles.

Hydrolytic breakdown of bioactive glass microcapsules releases medication over a month, eliminating daily application requirements.

A topical composition combines minoxidil, finasteride, and latanoprost to stimulate hair regrowth.

Tailored HPMC-AS polymers with unique substitution patterns overcome limited solubility enhancement in existing formulations.

Nasal pregnenolone targets chemosensory receptors to deliver rapid antidepressant action.

Azaindole derivatives disrupt the LEDGF/p75-integrase interaction, bypassing cross-resistance from conventional enzyme inhibitors.

Preventing adverse drug events from opicapone and quinidine interactions through preliminary anti-action protocols.

4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol inhibits NF-κB activity while sparing glucocorticoid receptors.

PDE1 inhibitors modulate intracellular cAMP and cGMP signaling pathways to reduce dyskinesias while sustaining motor symptom management.

Ranolazine administration reduces adverse coronary event risk in patients with elevated brain-type natriuretic peptide levels.

Ketal prodrugs delay onset via GI hydrolysis, reducing abuse potential while maintaining effective analgesia.

UCART22 cells delete the TRAC gene to resist anti-T cell drugs and reduce cytokine release syndrome while targeting refractory hematological cancers.

Aripiprazole mediates radiation effects to overcome cellular resistance and reduce normal tissue damage during cancer treatment.

Combining Ad36 E4orf1 with an AKT1 inhibitor improves glycemic control while blocking adipogenesis caused by PPARγ up-regulation.